Keyphrases
Anti-complement Therapy
11%
Autoimmune Myasthenia Gravis
11%
CD55
11%
Classical Complement Pathway
11%
Complement Activation
11%
Complement Regulatory Proteins
11%
Decay Accelerating Factor
100%
Direct Matching
11%
Extraocular muscles
100%
Flanking Region
11%
Functional Single nucleotide Polymorphism
100%
Gene Sequencing
11%
Immunosuppression
11%
Lipopolysaccharide-induced
11%
Luciferase Reporter
11%
Lymphoblast
11%
Muscle Damage
11%
Muscle Disease
11%
Muscle Paresis
100%
Myasthenia Gravis
100%
Myasthenic
11%
Sp1 Binding Site
11%
Susceptible Individuals
11%
Immunology and Microbiology
Binding Site
20%
Cell Line
10%
Classical Complement Pathway
10%
Complement Activation
10%
Decay-Accelerating Factor
100%
DNA Flanking Region
10%
Extraocular Muscle
100%
Gene Sequence
10%
Immunosuppression
10%
Lymphoblast
10%
Myasthenia gravis
100%
Prevalence
10%
Regulatory Region
100%
Single Nucleotide Polymorphism
100%
Transcription Factor
10%
Upregulation
20%
Neuroscience
Binding Site
20%
Blood Clotting Factor 5
10%
Cell Line
10%
Decay Accelerating Factor
100%
DNA Flanking Region
10%
Gene Sequence
10%
Immunosuppression
10%
Lipopolysaccharide
10%
Luciferase
10%
Lymphoblast
10%
Myasthenia gravis
100%
Paresis
100%
Regulator Protein
10%
Regulatory Region
100%
Single-Nucleotide Polymorphism
100%
Transcription Factors
10%
Biochemistry, Genetics and Molecular Biology
Binding Site
22%
Classical Complement Pathway
11%
Complement Activation
11%
Decay-Accelerating Factor
100%
DNA Flanking Region
11%
Factor V
11%
Gene Sequence
11%
Lipopolysaccharide
11%
Luciferase
11%
Lymphoblast
11%
Prevalence
11%
Regulatory Region
100%
Single-Nucleotide Polymorphism
100%
Transcription Factor
11%
Upregulation
22%